A phase 1b/3 randomized, double-blind, 3-stage study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma Meeting Abstract
| Authors: | Leonard, J.; Batlevi, C. L.; Gabrail, N.; Pagel, J. M.; Yang, J.; Whalen, J.; Adib, D.; Morschhauser, F. |
| Abstract Title: | A phase 1b/3 randomized, double-blind, 3-stage study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma |
| Meeting Title: | 8th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | lenalidomide; rituximab; lymphoma; b-cell lymphoma; ezh2; tazemetostat; relapsed/refractory follicular; ibcl; indolent b-cell lymphoma |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Sep 9-12 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-09-01 |
| Start Page: | S279 |
| Language: | English |
| ACCESSION: | WOS:000564055100278 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(20)30900-9 |
| Notes: | Meeting Abstract: IBCL-178 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
